Stifel Nicolaus started coverage on shares of eFFECTOR Therapeutics (NASDAQ:EFTR) in a research report sent to investors on Monday morning, Analyst Price Targets reports. The firm issued a hold rating and a $20.00 price target on the stock.
Separately, Cantor Fitzgerald assumed coverage on shares of eFFECTOR Therapeutics in a research report on Monday, September 13th. They set an overweight rating and a $50.00 target price for the company.
Shares of NASDAQ:EFTR opened at $17.86 on Monday. eFFECTOR Therapeutics has a one year low of $8.33 and a one year high of $40.42.
Locust Walk Acquisition Corp. entered into a definitive business combination agreement with eFFECTOR Therapeutics Inc
Featured Story: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for eFFECTOR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eFFECTOR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.